Given its role in promoting cancer cell survival, Bcl-2 is an attractive target for cancer therapy. Bcl-2 inhibitors are a class of drugs designed to block the function of Bcl-2, thereby promoting apoptosis in cancer cells. One of the most well-known Bcl-2 inhibitors is venetoclax, which has been approved for the treatment of certain types of CLL and acute myeloid leukemia (AML). These drugs have shown promise in clinical trials, providing a new avenue for treating malignancies that overexpress Bcl-2.
